Fondazione G.B. Bietti, IRCCS   Report issue

Foundation Phase 2 Phase 4
Founded: Rome Italy (1984)

Organization Overview

First Clinical Trial
2005
NCT00404729
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fondazione Bietti- IRCCS | Fondazione G.B. Bietti, IRCCS | Fondazione G.B. Bietti-IRCCS, Rome, Italy | IRCCS G.B.Bietti Foundation for the study and Research in Ophthalmology ONLUS | IRCSS Fondazione Bietti

Active Ingredients

Drugs in Phase 4 Trials (3)

citicoline (5 trials)

tafluprost (zioptan) (1 trial)

timolol (blocadren) (1 trial)

Drugs in Phase 2 Trials (2)

ranibizumab (lucentis) (1 trial)

verteporfin (visudyne) (1 trial)

Drugs in Other Trials (4)

dexamethasone (1 trial)

hyaluronic acid (1 trial)

lutein (1 trial)

zeaxanthin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 4)

Macular Degeneration (Phase 2)

Optic Nerve Diseases (Phase 4)

Optic Neuropathy, Ischemic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 9